## **Electronic Supplementary Material**

Cellular and Molecular Life Sciences

## Key role of integrin $\alpha_{IIb}\beta_3$ signaling to Syk kinase in tissue factor-induced thrombin generation

Paola E.J. van der Meijden<sup>1</sup>, Marion A.H. Feijge<sup>1\*</sup>, Frauke Swieringa<sup>1\*</sup>, Karen Gilio<sup>1</sup>, Reyhan Nergiz-Unal<sup>1</sup>, Karly Hamulyák<sup>2</sup> and Johan W.M. Heemskerk<sup>1\*\*</sup>

<sup>1</sup>Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM); <sup>2</sup>Haemostasis Laboratory, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

\*M.A.H.F. and F.S. contributed equally
\*\*Corresponding author: Johan W. M. Heemskerk PhD, Dep. Biochemistry (CARIM), Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands.
Tel: +31-43-3881671, fax: +31-43-3884159; e-mail: jwm.heemskerk@maastrichtuniversity.nl



Fig. 1 Blocking of  $\alpha_{IIb}\beta\beta$  suppresses tissue factor-triggered thrombin generation in the presence of platelets. Human PRP ( $1.0 \times 10^8$  platelets/mL) or PFP supplemented with phospholipid vesicles (PV, 10  $\mu$ M) was preincubated with vehicle, abciximab (0.5-20  $\mu$ g/mL) or eptifibatide (0.1-20  $\mu$ g/mL) for 20 minutes. Thrombin generation was stimulated with tissue factor  $\mu$  and CaCl<sub>2</sub>. **a** Representative thrombin generation curves with PRP, showing comparable effects of all integrin blockers. **b** Dose-dependent inhibition of thrombin generation only in the presence of platelets. Means ± SEM (*n*=3-9)



**Fig. 2** Impaired spreading and thrombin activation of Glanzmann platelets. Platelets from healthy control subjects and Glanzmann patients were adhered to fibrinogen in the absence (control) or presence of tirofiban (1  $\mu$ g/mL) for 30 minutes, and then stimulated with thrombin (10 nM) for another 10 minutes. **a** Representative phase contrast (120×120  $\mu$ m) and FITC-annexin A5 fluorescence (150×150  $\mu$ m) images after thrombin activation. **b** Averaged platelet size; **c** fractions of PS-exposing platelets after activation. Means ± SEM (*n*=3-6); \**p*<0.05 *vs.* vehicle



**Fig. 3** Syk kinase is responsible for thrombin generation in tissue factor-stimulated PRP of a Glanzmann patient. PRP was incubated with vehicle, Syk inhibitor II (10  $\mu$ M), iloprost (1  $\mu$ M) and/or tirofiban (1  $\mu$ g/mL), and then stimulated with tissue factor (1 pM) and CaCl<sub>2</sub>. Cangrelor (AR-C, 10  $\mu$ M) was present to eliminate P2Y<sub>12</sub>-dependent signaling events. **a**, **b** Effect of inhibitors on tissue factor-induced thrombin generation in PRP from blood samples collected on citrate, and **c**, **d** on citrate and tirofiban (1  $\mu$ g/mL). Representative thrombin generation curves and mean thrombin peak heights of triplicate measurements are shown.